Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):583-591. doi: 10.1016/j.ijrobp.2018.10.021. Epub 2018 Oct 24.
PURPOSE: The primary goal was to map the anatomic pattern of isolated nodal recurrences (NR) in the supraclavicular (SCV), axillary, and internal mammary nodes (IMNs) in patients with breast cancer treated with curative-intent surgery with or without radiation therapy (RT). Secondary objectives were to assess clinical and pathologic factors associated with patterns of NR and survival rates. METHODS AND MATERIALS: Patients with NR after treatment at a single cancer center during 1998 to 2013 were identified. Patients with prior distant metastases or NR without correlative imaging were excluded. All NRs were overlaid onto representative axial computed tomographic images. Multivariable analysis was performed to identify clinical and pathologic characteristics associated with NR. Kaplan-Meier curves were generated to assess the rate of relapse by nodal region according to pathologic feature or radiation treatment status. RESULTS: The locations of 243 NRs among 153 eligible patients were mapped. The majority of NR occurred in the axilla (42%; 102/243), followed by the IMN (32.5%; 79/243) and the SCV (25.5%; 62/243). Radiation Therapy Oncology Group (RTOG) or European Society for Radiation therapy and Oncology (ESTRO) clinical target volume encompassed 82% (198/243) of NRs. The majority of out-of-field NRs were located in the lateral and posterior SCV region for both RTOG (67%; 30/45) and ESTRO (89%; 49/55) guidelines. The high-risk patients who received regional RT to the SCV relapsed at a similar rate in the medial, but a higher rate in lateral SCV (P = .009), compared with low-risk patients who received no nodal RT. Lymphovascular invasion most strongly associated with IMN NR (P = .001); grade 3 disease highly associated with both IMN (P = .001) and SCV NR (P = .02). The presence of an IMN NR portended for significantly inferior overall survival (OS), compared with an axillary NR, with a 5-year OS of 59% versus 72%, respectively (P = .03). CONCLUSIONS: In this 3-dimensional image-based analysis of NR patterns in breast cancer patients treated with contemporary therapies, the lateral and posterior SCV represented a distinct site of NR that is not routinely included within current breast cancer contouring atlases. Grade 3 breast cancer and LVI were most commonly associated with the development of NR in the SCV. Modifying the CTV to encompass the lateral and posterior SCV in patients with breast cancer with these features might be justified.
目的:本研究旨在描绘接受根治性手术治疗的乳腺癌患者中,锁骨上区(SCV)、腋窝和内乳区(IMN)孤立性淋巴结复发(NR)的解剖模式。次要目标是评估与 NR 模式和生存率相关的临床和病理因素。 方法和材料:在 1998 年至 2013 年期间,我们在单一癌症中心对接受治疗后出现 NR 的患者进行了识别。排除了先前有远处转移或无相关影像学检查的 NR 患者。所有 NR 均叠加到代表性的轴向 CT 图像上。采用多变量分析来确定与 NR 相关的临床和病理特征。Kaplan-Meier 曲线用于根据病理特征或放射治疗状态评估按淋巴结区域计算的复发率。 结果:在 153 名符合条件的患者中,有 243 个 NR 的位置被定位。大多数 NR 发生在腋窝(42%;102/243),其次是 IMN(32.5%;79/243)和 SCV(25.5%;62/243)。放射治疗肿瘤学组(RTOG)或欧洲放射治疗和肿瘤学学会(ESTRO)临床靶区涵盖了 243 个 NR 中的 82%(198/243)。对于 RTOG(67%;30/45)和 ESTRO(89%;49/55)指南,大多数超出靶区的 NR 位于 SCV 的外侧和后侧。与未接受淋巴结区域放射治疗的低危患者相比,接受 SCV 区域放射治疗的高危患者在内侧的复发率相似,但在 SCV 外侧的复发率更高(P=.009)。淋巴管血管侵犯与 IMN NR 关系最密切(P=.001);3 级疾病与 IMN(P=.001)和 SCV NR(P=.02)均高度相关。与腋窝 NR 相比,IMN NR 预示着整体生存率(OS)显著降低,5 年 OS 分别为 59%和 72%(P=.03)。 结论:在对接受当代治疗的乳腺癌患者进行的基于 3 维图像的 NR 模式分析中,SCV 的外侧和后侧代表了一个独特的 NR 部位,这在当前的乳腺癌勾画图谱中并未常规包括。3 级乳腺癌和 LVI 是 SCV 中 NR 发展最常见的相关因素。对于具有这些特征的乳腺癌患者,修改 CTV 以包含 SCV 的外侧和后侧可能是合理的。
Int J Radiat Oncol Biol Phys. 2018-10-24
Pract Radiat Oncol. 2023
Int J Radiat Oncol Biol Phys. 2015-10-1
Int J Radiat Oncol Biol Phys. 2018-8-14
Q J Nucl Med Mol Imaging. 2014-6
Radiat Oncol. 2020-6-1
Int J Radiat Oncol Biol Phys. 2015-7-1
Int J Radiat Oncol Biol Phys. 2021-10-1
Radiother Oncol. 2021-7
Int J Radiat Oncol Biol Phys. 2017-3-15
Int J Radiat Oncol Biol Phys. 2015-10-1
Int J Radiat Oncol Biol Phys. 2015-10-1
N Engl J Med. 2015-7-23
N Engl J Med. 2015-7-23
Int J Radiat Oncol Biol Phys. 2015-7-1